Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.47, marking a -0.8% move from the previous day.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Company News for Sep 13, 2022
by Zacks Equity Research
Companies in The News Are: AAPL, BMY, TWTR, GILD
Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $69.38 in the latest trading session, marking a +0.9% move from the prior day.
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
by Zacks Equity Research
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
Bristol Myers Squibb (BMY) Stock Moves -0.69%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $68.61 in the latest trading session, marking a -0.69% move from the prior day.
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
by Zacks Equity Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
by Zacks Equity Research
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.
The Zacks Analyst Blog Highlights Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna
by Zacks Equity Research
Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna are part of The Zacks top Analyst Blog.
Top Analyst Reports for Apple, Alibaba & Bristol-Myers Squibb
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and Bristol-Myers Squibb Company (BMY).
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Bristol Myers (BMY) Posts Data From Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.